SUNNYVALE, Calif. , Oct. 30 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that 28 CyberKnife-focused abstracts have been accepted as part of the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO),
Large Scale Study Results Presented in Prostate, Lung and Brain Tumor Treatment SUNNYVALE, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced key clinical presentation highlights from the 7th Annual CyberKnife
Total CyberKnife Patients Treated Rises to More Than 30,000 SUNNYVALE, Calif., May 8 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the CyberKnife(R) Robotic Radiosurgery System install base has reached 100 systems.
SUNNYVALE, Calif., Feb. 14, 2011 /PRNewswire via COMTEX/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today the completion of the annual CyberKnife Scientific Meeting held February 10-12, 2011 , in San Francisco, Calif.
U.S. Patients Treated with CyberKnife System for Lung Cancer Doubled and Prostate Cancer Quadrupled SUNNYVALE, Calif., Aug. 8 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that use of its CyberKnife(R) Robotic
Accuray Achieves Patient Treatment Milestone on Third Anniversary of National Prostate Cancer Awareness Month SUNNYVALE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that more than 1,000 men have been
Enhanced Capabilities Enable More Patients to Benefit from CyberKnife Treatment SUNNYVALE, Calif., Oct 29, 2010 /PRNewswire via COMTEX/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today feedback from Creekside Cancer Care on their use of the
Long Term Outcomes for Intermediate-Risk Prostate Cancer Patients SUNNYVALE, Calif. , June 7, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that outcome data on intermediate risk prostate cancer patients treated with CyberKnife®
Prospective, Multi-institutional Study Shows CyberKnife SBRT Treatment Results in Low PSA Nadir for Low- and Intermediate-risk Prostate Cancer Patients SUNNYVALE, Calif. , Feb. 16, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective, Phase II, 17-center
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
